Short Interest in PDS Biotechnology Corporation (NASDAQ:PDSB) Rises By 61.8%

PDS Biotechnology Corporation (NASDAQ:PDSB) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totaling 2,172,765 shares, a growth of 61.8% from the December 31st total of 1,343,277 shares. Based on an average trading volume of 898,913 shares, the days-to-cover ratio is presently 2.4 days. Approximately 4.9% of the shares of the stock are short sold. Approximately 4.9% of the shares of the stock are short sold. Based on an average trading volume of 898,913 shares, the days-to-cover ratio is presently 2.4 days.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PDSB. HC Wainwright raised their target price on PDS Biotechnology from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. Finally, B. Riley dropped their target price on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, November 25th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, PDS Biotechnology has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Price Performance

PDSB stock traded down $0.04 during mid-day trading on Friday, reaching $0.83. 391,212 shares of the company traded hands, compared to its average volume of 863,702. PDS Biotechnology has a 52-week low of $0.70 and a 52-week high of $2.20. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.09 and a quick ratio of 2.09. The company has a market capitalization of $40.79 million, a P/E ratio of -1.02 and a beta of 1.12. The company has a fifty day moving average price of $0.89 and a 200-day moving average price of $1.01.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.02. As a group, analysts anticipate that PDS Biotechnology will post -1.2 earnings per share for the current year.

Institutional Trading of PDS Biotechnology

A number of large investors have recently made changes to their positions in the stock. Tempus Wealth Planning LLC boosted its stake in PDS Biotechnology by 29.3% during the fourth quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock valued at $48,000 after buying an additional 14,000 shares during the last quarter. Susquehanna International Group LLP raised its holdings in PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of PDS Biotechnology by 116.1% during the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares during the last quarter. Inspirion Wealth Advisors LLC boosted its holdings in PDS Biotechnology by 338.5% in the third quarter. Inspirion Wealth Advisors LLC now owns 344,394 shares of the company’s stock worth $348,000 after acquiring an additional 265,862 shares in the last quarter. Finally, Watts Gwilliam & Co. LLC acquired a new stake in PDS Biotechnology in the 2nd quarter worth approximately $73,000. 26.84% of the stock is currently owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical?stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen?presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS?0101, is designed to treat HPV16?positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV?focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.